Objectives: Critical hand ischemia caused by below-the-elbow atherosclerotic occlusive disease is increasing. The aim of this study was to examine the patient-centered outcomes of open and endovascular interventions in patients presenting with critical ischemia.
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Distal Vein Patch Use and Limb Events Following Infragenicular Prosthetic Bypasses
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Objectives: In the absence of suitable autologous vein, prosthetic grafts are commonly used as alternate conduits for infragenicular bypasses. The primary purpose of this study was to investigate whether use of vein patch adjuncts decreased the incidence of subsequent major adverse limb events (MALEs).
Methods: All patients undergoing infragenicular prosthetic bypass grafts between January 2009 and July 2016 were retrospectively reviewed. Patient demographics, clinical data, and outcomes (MALE and graft patency) were collected. Patients were compared according to treatment group (patch vs no patch). Kaplan-Meier curves were used to analyze follow-up results.
Results: Over the study period, 373 patients underwent infragenicular bypass at our institution. Of those, 93 (24.9%) had prosthetic grafts: 39 with patch and 54 without patch. Overall, 92 patients (98.9%) were male, with a mean age of 63 years. Age and the rates of comorbidities, such as hypertension, chronic obstructive pulmonary disease, diabetes mellitus, and end-stage renal disease, did not differ between the two groups. Median follow-up time was 7.8 months (range, 1-89 months). Reintervention rates were significantly higher in the no patch group (50% vs 31%; odds ratio, 2.3; 95% confidence interval, 1.1-10.7; P ¼ .04). When occluded, patients in the no patch group more often presented with acute limb ischemia (43% vs 30%; odds ratio, 1.4; 95% confidence interval, 0.7-3.1; P ¼ .34). Kaplan-Meier curves demonstrated an improved freedom from MALE in the vein patch group that did not reach significance (log-rank P ¼ .269; Fig) . The higher primary patency in the vein patch group did not reach significance (46% vs 35%; P ¼ .206).
Conclusions: Use of a distal vein patch demonstrates significantly reduced reintervention rates and a somewhat decreased incidence of acute limb ischemia. This may represent a benefit beyond a previouslydemonstrated improvement in patency.
Author Disclosures: N. R. Barshes: Nothing to disclose; J. Braun: Nothing to disclose; B. Castelo Branco: Nothing to disclose; P. Kougias: Nothing to disclose; J. Mills: Nothing to disclose. Objectives: Major lower extremity amputations (MLEA) are on the rise despite increased attention placed on prevention. It is unknown whether postamputation functional outcomes, ambulation, and the ability to predict these outcomes have changed with an increasingly aging and obese patient population. Accordingly, we sought to evaluate contemporary trends.
VESS21.
Defining Predictors of Ambulation and
Methods: A retrospective record review was performed to identify patients undergoing MLEA using Current Procedural Terminology codes in a university hospital. Demographics, comorbidities, perioperative variables, and outcomes were obtained. Descriptive statistics, t-tests, c 2 , and multivariate logistic regression modeling were used where appropriate. Survival analyses were performed with the Kaplan-Meier method.
Results Conclusions: Patients should be counseled that <50% of those undergoing MLEA are ambulatory postamputation and on the negative effect of obesity on ambulatory status. Efforts to reduce obesity may further improve ambulatory status in these patients.
Author Disclosures: C. Abraham: Nothing to disclose; A. Chopra: Nothing to disclose; E. Jung: Nothing to disclose; G. Landry: Nothing to disclose; T. Liem: Nothing to disclose; E. Mitchell: Nothing to disclose; G. Moneta: Nothing to disclose. Objectives: Initial data on drug-eluting stents (DES) shows they may increase durability of endovascular treatment of superficial femoral artery (SFA) disease compared to traditional bare-metal stents (BMS). Observed decreased target lesion revascularization (TLR) rates have potential for savings despite increased initial costs. The purpose of this study was to simulate a transition from BMS to DES over 5 years, evaluating the overall cost impact of that transition.
VESS22.
Implementation of Drug-Eluting Stents for the
Methods: Florida state ambulatory databases were searched for patients undergoing SFA stenting in 2013 (Current Procedural Terminology codes 37226 and 37227). A model was developed to estimate the impact of progressive transition from BMS to DES over a 5-year horizon in this population. Cost estimates were determined from available cost-tocharge ratios. 2013 was the initial year for the model with each subsequent year based on the expected number of interventions per year. Up to one TLR per patient was assumed for the model. TLR rates for DES and other parameter estimates were based on pooled data from the literature. Institutional data were used to estimate that up to 48% of lesions would fit the instructions for use for the Zilver PTX, currently the only United States Food and Drug Administration-approved DES for peripheral interventions. Net budget impact was expressed as difference in total costs (primary stenting and reinterventions) for a scenario where BMS is progressively replaced by Zilver PTX compared to a scenario of BMS only. Multiple sensitivity analyses were performed on the base scenario.
Results: A total of 4107 peripheral interventions fit our study. Overall cost for these procedures in the Florida database was $51,362,142.00. In the base case, DES was introduced at a rate of 8% per year up to 48% at the end of the model. This resulted in an overall cost savings of $1,688,953.72 compared to the model with BMS alone. Net budget impact by year with DES vs BMS only is illustrated in the Fig, where a negative net budget impact indicates savings. Sensitivity analyses, including slower adoption of DES up to 24% at 5 years, a 20% increase in TLR rates per year for the DES, and a 10% reduction in TLR rates per year for BMS still resulted in a net savings. As long as the additional cost of a DES compared to BMS is less than $677, the DES model remains less expensive.
Conclusions: The adoption of drug eluting stents in lieu of traditional BMS can lead to significant cost savings in a single state system over a short time horizon. 
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Objectives: It is not clear whether endovascular repair of abdominal aortic aneurysms (EVAR) results in more decline in renal function over the long-term when compared to open repair (OR). We reviewed our experience with abdominal aortic aneurysm (AAA) repair to determine whether there was a significant difference in immediate postoperative and long-term renal outcomes between OR and EVAR.
Methods: A retrospective cohort study was conducted on all patients who underwent AAA repair between January 1993 and July 2013 at a tertiary referral hospital. Demographics, comorbidities, preoperative and postoperative laboratory values, morbidity, and mortality were collected. Patients with ruptured AAAs, preoperative hemodialysis, juxtarenal or suprarenal aneurysm origin, and no follow-up laboratory values were excluded. Preoperative, postoperative, 6-month, and yearly serum creatinine values were collected. Glomerular filtration rate (GFR) was calculated based on the Chronic Kidney Disease Epidemiology Collaboration equation. Acute kidney injury (AKI) was classified using the Kidney Disease: Improving Global Outcomes guidelines. D GFR was defined as preoperative GFR minus the GFR at each follow-up interval. Comparison was made between EVAR and OR groups using multivariate logistics for categoric data and linear regression for continuous variables. 
